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ABSTRACT
Introduction Variable use of new molecular assays,
asymptomatic infections and a lack of population data
mean that the population burden of Trichomonas
vaginalis is uncertain. We investigated the age-speciﬁc
prevalence of T. vaginalis within the sexually active
British general population to inform testing strategies.
Methods Britain’s third National Survey of Sexual
Attitudes and Lifestyle (Natsal-3) is a probability sample
survey of 15 162 individuals aged 16–74 years,
undertaken during 2010–2012. Urine from 4386
participants aged 16–44 years reporting ≥1 lifetime
sexual partner was tested for T. vaginalis using in-house
real-time PCR.
Results Urinary T. vaginalis was detected in seven
women and no men providing urine samples, giving a
weighted prevalence estimate of 0.3% (95% CI 0.1% to
0.5%) in sexually experienced women aged 16–
44 years. Of the seven women with T. vaginalis
detected, four were of black or mixed ethnicity
(prevalence 2.7% (0.9% to 7.7%) in this group) and
ﬁve reported recent partners of black or mixed ethnicity.
Six of the women reported symptoms, and ﬁve reported
sexual health clinic attendance in the past 5 years
(prevalence in those reporting clinic attendance: 1.0%
(0.4% to 2.3%)). The prevalence of a self-reported
history of T. vaginalis ( past 5 years) was 0.1% (0.0% to
0.2%) in women and 0.0% (0.0% to 0.2%) in men
aged 16–44 years.
Conclusions Our British population prevalence
estimates indicate that T. vaginalis is a rare infection.
These data support policies that restrict asymptomatic
screening for T. vaginalis and suggest deployment of
molecular tests should be focused within clinical settings
and guided by symptoms and local demography.
INTRODUCTION
Trichomonas vaginalis is a sexually transmitted
protozoan, which adheres to mucous membranes of
the vagina and male urethra to cause trichomonia-
sis. Globally, T. vaginalis is the single most preva-
lent non-viral STI. Indeed, the WHO estimated
that more than 270 million cases occurred in 2008,
greater than the combined total for chlamydia and
gonorrhoea.1 However, T. vaginalis diagnosis is
relatively rare in the UK, with around 6000 cases
reported each year, compared with over 200 000
chlamydia cases.2 3
National STI surveillance data in England show
that over 90% of diagnosed T. vaginalis cases occur
in women,2 3 a gender disparity attributed to more
rapid spontaneous clearance of infection in
men. Between 2009 and 2011, just under half of
T. vaginalis diagnoses were in women of white
ethnicity (in whom the rate was 10.7/100 000
population), but the rate of T. vaginalis diagnoses
was much higher in black Caribbean women
(329.6/100 000) and women of other black ethnici-
ties (498.4/100 000), and much lower in men
(33.9/100 000 in black Caribbean men and 0.6/
100 000 in white men).2 However, diagnosis data
are limited for a number of reasons, including that
asymptomatic individuals may not seek healthcare,
so the extent to which there might be a pool of
undiagnosed infection in the wider population is
unknown.
The BASHH 2014 guidelines recommend testing
women according to clinical signs and symptoms,
and men with persistent urethritis and/or who are
contacts of individuals diagnosed with T. vaginalis.4
Widespread screening for T. vaginalis was previ-
ously limited because of a reliance on diagnostic
assays, such as culture or wet mounts, which lack
sensitivity and are time consuming. However,
molecular assays with enhanced sensitivity are now
readily available, either commercially or in-house,
raising important questions about deployment of
such tests for diagnostic and screening purposes.
The third National Survey of Sexual Attitudes
and Lifestyles (Natsal-3) is a probability sample
survey, which included urine testing and reported
history of diagnoses to estimate the prevalence for
a range of STIs.5 Natsal-3 used molecular assays for
T. vaginalis to enable description of the age-speciﬁc
and gender-speciﬁc prevalence of T. vaginalis
within the sexually active British general population
to inform clinical practice and public health policy.
METHODS
Participants and survey procedures
Natsal-3 was a stratiﬁed probability sample survey
of 15 162 men and women aged 16–74 years in
Britain who were interviewed during 2010–
2012.6 7 The estimated overall response rate was
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57.7%, and the cooperation rate was 65.8% (of all eligible
addresses contacted). Participants were interviewed in their own
homes using computer-assisted personal interview and
computer-assisted self-interview (CASI). The CASI included
questions about participants’ sexual behaviour, their history of
being diagnosed with STIs by a healthcare professional and
their experience of genital symptoms associated with STIs in the
month before interview. After the interview, we invited a sample
of participants aged 16–44 years to provide urine for STI
testing. Full methodological details have been described else-
where.5–7
Laboratory methods
In 2013, we undertook anonymous testing for T. vaginalis,
without return of results, on DNA extracts taken from urine
samples where there was sufﬁcient sample (4482 out of 4550
participants) and where participants had provided consent for
storage (4386 out of 4482 participants). All DNA extracts were
screened using a modiﬁed primary RT-PCR that detects a 92-bp
repeat-region fragment of T. vaginalis DNA,8 9 and samples that
generated a positive or equivocal screening result were retested
with a secondary RT-PCR, which targets a conserved portion of
the T. vaginalis β-tubulin gene.9 10 A conﬁrmed positive result
was deemed to be one where the ﬁrst RT-PCR was positive or
equivocal and the second RT-PCR was positive.
Statistical analysis
Prevalence estimates with 95% CIs in women and men are
reported by age group for T. vaginalis detected in urine, and
self-reported T. vaginalis diagnoses over the lifetime and in the
past 5 years. Survey analyses were done in Stata V.13 accounting
for sample stratiﬁcation, clustering and weighting. Analyses were
additionally weighted for unequal urine selection probabilities
and differential urine sample response.5–7
RESULTS
Urinary T. vaginalis test results were available from 4386 sexu-
ally active participants (2559 women; 1827 men; 54.5% of all
eligible participants) aged 16–44 years. The primary screening
test detected T. vaginalis DNA in seven samples, all of which
were conﬁrmed with the secondary test. All seven samples were
from women (there were no positive tests in men), giving a
weighted prevalence estimate of 0.3% (95% CI 0.1% to 0.5%)
in women aged 16–44 years (table 1). The prevalence of T. vagi-
nalis in women decreased with age group, with the highest
prevalence (0.6% (0.2% to 1.7%)) in those aged 16–24 years.
Two women with T. vaginalis were coinfected with chlamydia,
and two had at least one human papilloma virus-type detected;
none of the women had Neisseria gonorrhoeae, HIV or
Mycoplasma genitalium detected.5 w1 w2
Although small numbers prevent detailed characterisation of
cases, we observed that four of the seven women were of black
or mixed ethnic origin, giving a weighted prevalence of 2.7%
(0.9% to 7.7%) in this broad ethnicity group. All seven women
reported at least one opposite sex partner in the past 5 years.
The four women of black or mixed ethnicity and one white
woman reported partners who were of black, black British or
mixed ethnicity. Five of the women reported attending a sexual
health clinic in the past 5 years (for three, this was in the past
year), giving an estimated weighted prevalence of 1.0% (0.4%
to 2.3%) among clinic attendees (past 5 years). Six of the
women reported symptoms (abnormal or odorous vaginal dis-
charge, or lower abdominal, or pelvic pain) in the month before
interview. None reported a previous diagnosis of T. vaginalis.
Of 13 658 Natsal participants aged 16–74 years who reported
at least one lifetime partner, 0.5% (0.3% to 0.7%) of women
and 0.0% (0.0% to 0.2%) of men reported a T. vaginalis diag-
nosis in their lifetime (corresponding to 36 women and 3 men)
(table 2). Among women, reported lifetime diagnosis of T. vagi-
nalis was more common in those aged 45–74 years (0.8%
(0.5% to 1.2%) compared with those aged 16–44 years (0.2%
(0.1% to 0.4%); p=0.0018). However, diagnosis in the past
5 years was only reported by younger people (six women and
two men), with an estimated prevalence in those aged 16–
44 years of 0.1% (0.0% to 0.2%) in women and 0.0% (0.0% to
0.2%) in men.
DISCUSSION
This study provides the ﬁrst population-based prevalence
estimates for T. vaginalis in the British general population and
indicates that T. vaginalis is an uncommon infection. A molecu-
lar assay with conﬁrmatory testing was used, and we detected
T. vaginalis in only a small number of women in a large sample,
which was broadly representative of the sexually active general
population. All cases except two were in women of Black or
mixed ethnicity, or reported recent partners of Black or mixed
ethnicity, and most had symptoms consistent with infection.
Most had recently attended a sexual health clinic. These data
are supported by our ﬁnding that the prevalence of reported
T. vaginalis diagnosis in the past 5 years in those aged 16–
44 year was also very low.
In this cross-sectional study, the use of urine, which is a sub-
optimal specimen for the detection of T. vaginalis, particularly
in men, might have led to underestimation of prevalence.w3 w4
DNA extracts were stored for up to 3 years before testing, intro-
ducing a small risk of degradation, which might have reduced
assay sensitivity. While the size and representative nature of the
sample are important strengths of this study, Natsal-3 did not
include an ethnic boost, and the total number of non-white par-
ticipants was relatively small. This meant that subanalyses were
Table 1 Prevalence of T. vaginalis in urine in participants aged 16–44 years, by age group and gender
Women Men
Denominator
women
Denominator
men
Per cent CI Per cent CI Unwt Wt Unwt Wt
16–24 0.6 (0.2% to 1.7%) 0 958 576 818 604
25–34 0.3 (0.1% to 1.0%) 0 1097 774 668 778
35–44 0.0 0 504 838 341 809
Total 0.3 (0.1% to 0.5%) 0 2559 2188 1827 2191
Unwt, unweighted; wt, weighted.
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not possible, and underrepresentation of these groups might
also have led to underestimation of prevalence.
Worldwide data sets providing robust estimates of T. vaginalis
prevalence in the general population are limited to the USA.
The 2001–2002 Add Health study found the prevalence in
women aged 18–26 years was 2.8% (2.2% to 3.6%).w5 The
2001–2004 NHANES study reported that the prevalence in
women aged 14–49 years was 3.1% (2.2% to 4.3%), driven by
very high prevalence in women of non-Hispanic black ethnicity
(13.3% (10.0–17.7).w6 A probability sample of young adults
undertaken in Baltimore in 2006–2009 reported that prevalence
was 4.1% (2.3% to 7.0%) in non-black women and 16.6%
(13.0% to 19.8%) in women of black ethnicity.w7 The use of
different samples and assays in these studies complicates com-
parison, but it is striking that the US data consistently show
much higher prevalence estimates than we found in Britain.
Differences in the demographic composition of the USA and
British populations might partially account for these ﬁndings,
but we note that prevalence estimates in black women in the
Natsal sample are also lower, which might be explained by dif-
ferences in access to healthcare. Overall higher rates of STIs
found in black populations might also be due to differences in
sexual behaviour (eg, overlapping partnerships and assortative
mixing), and associated with underlying social factors such as
deprivation.w8
These data are timely because molecular assays to detect
T. vaginalis are now commercially available, increasing the feasi-
bility of widespread screening, including outside of specialist
sexual health services. However, given the very low prevalence
detected, unselected screening of asymptomatic individuals is
unlikely to represent a cost-effective use of resources. Instead,
these data support policies that focus the deployment of molecu-
lar tests within clinical settings where pilot studies and/or demog-
raphy provide evidence of higher prevalence in the local
community. It is now the role of professional clinical and public
health organisations to take these ﬁndings, together with other
published evidence, to make recommendations about T. vaginalis
screening and diagnostic testing.
Ethical approval
We obtained ethics approval from Oxfordshire Research Ethics
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